Compound information
- Natural Products
- NACP131269
- Molecular Formula
- C18H28O3
- Molecular Weight
- 292.203844756 g/mol
- Structure
-
- IUPAC Name
- 16-oxooctadeca-9,12,14-trienoic acid
- InChI
- InChI=1S/C18H28O3/c1-2-17(19)15-13-11-9-7-5-3-4-6-8-10-12-14-16-18(20)21/h3,5,9,11,13,15H,2,4,6-8,10,12,14,16H2,1H3,(H,20,21)
- InChI Key
- UDNFCQRCBRMBQF-UHFFFAOYSA-N
- SMILES
- O=C(O)CCCCCCCC=CCC=CC=CC(=O)CC
- CAS
- SuperClass
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- SubClass
- Lineolic acids and derivatives
- Source
- CNP0086877
Warheads
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 21 | Ring Count | 0 |
| Heteroatom Count | 3 | Rotatable Bond Count | 13 |
| Hydrogen Bond Acceptor Count | 2 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 54.37 Å2 | LogP | 4.827 |
| LogS | -3.98 | LogD | 3.011 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.434 | Pgp substrate | 0.001 |
| HIA | 0.978 | F20 % | 0.988 |
| F30 % | 0.405 | Caco-2 | -4.81 |
| MDCK | -4.59 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.987 | PPB | 81.219 |
| VD | 0.512 | Fu | 1.35 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.863 | CYP1A2 substrate | 0.312 |
| CYP2A6 substrate | 0.375 | CYP2B6 substrate | 0.501 |
| CYP2C19 inhibitor | 0.053 | CYP2C19 substrate | 0.359 |
| CYP2C8 substrate | 0.54 | CYP2C9 inhibitor | 0.519 |
| CYP2C9 substrate | 0.019 | CYP2D6 inhibitor | 0.105 |
| CYP2D6 substrate | 0.132 | CYP2E1 substrate | 0.205 |
| CYP3A4 inhibitor | 0.086 | CYP3A4 substrate | 0.028 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.916 | CL | 2.897 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.681 | Hepatotoxicity | 0.957 |
| Mutagenicity | 0.067 | Rat Oral Acute Toxicity | 0.013 |
| FDAMDD | 0.395 | Skin Sensitization | 0.991 |
| Carcinogenicity | 0.873 | Eye Corrosion | 0.475 |
| Eye Irritation | 0.962 | Respiratory Toxicity | 0.413 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.954 | IGC50 | 3.918 |
| LC50FM | 5.434 | LC50DM | 6.053 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.231 | NR-AR-LBD | 0.386 |
| NR-AhR | 0.004 | NR-Aromatase | 0.073 |
| NR-ER | 0.247 | NR-ER-LBD | 0.35 |
| NR-PPAR-gamma | 0.908 | SR-ARE | 0.915 |
| SR-ATAD5 | 0.357 | SR-HSE | 0.804 |
| SR-MMP | 0.027 | SR-p53 | 0.566 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.